201 related articles for article (PubMed ID: 38287839)
21. Identification of biomarkers in patients with rheumatoid arthritis responsive to DMARDs but with progressive bone erosion.
Marasco E; Fabbriciani G; Rotunno L; Longhi M; De Luca P; de Girolamo L; Colombini A
Front Immunol; 2023; 14():1254139. PubMed ID: 37809106
[TBL] [Abstract][Full Text] [Related]
22. The interplay between inflammation and metabolism in rheumatoid arthritis.
Chimenti MS; Triggianese P; Conigliaro P; Candi E; Melino G; Perricone R
Cell Death Dis; 2015 Sep; 6(9):e1887. PubMed ID: 26379192
[TBL] [Abstract][Full Text] [Related]
23. New therapeutic options in rheumatoid arthritis: a focus on interleukin-6 blockade.
Furfaro N
J Infus Nurs; 2011; 34(2):107-15. PubMed ID: 21399456
[TBL] [Abstract][Full Text] [Related]
24. Rheumatoid arthritis: developing pharmacological therapies.
Abbott JD; Moreland LW
Expert Opin Investig Drugs; 2004 Aug; 13(8):1007-18. PubMed ID: 15268638
[TBL] [Abstract][Full Text] [Related]
25. An overview of immunomodulatory intervention in rheumatoid arthritis.
Kavanaugh A
Drugs Today (Barc); 1999; 35(4-5):275-86. PubMed ID: 12973432
[TBL] [Abstract][Full Text] [Related]
26. Periodontal Disease as a Risk Factor for Rheumatoid Arthritis: A Systematic Review.
Kaur S; White S; Bartold M
JBI Libr Syst Rev; 2012; 10(42 Suppl):1-12. PubMed ID: 27820156
[TBL] [Abstract][Full Text] [Related]
27. Understanding the role of cytokines in the pathogenesis of rheumatoid arthritis.
Mateen S; Zafar A; Moin S; Khan AQ; Zubair S
Clin Chim Acta; 2016 Apr; 455():161-71. PubMed ID: 26883280
[TBL] [Abstract][Full Text] [Related]
28. The roles of the classical and alternative nuclear factor-kappaB pathways: potential implications for autoimmunity and rheumatoid arthritis.
Brown KD; Claudio E; Siebenlist U
Arthritis Res Ther; 2008; 10(4):212. PubMed ID: 18771589
[TBL] [Abstract][Full Text] [Related]
29. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
[TBL] [Abstract][Full Text] [Related]
30. Strategies toward rheumatoid arthritis therapy; the old and the new.
Abbasi M; Mousavi MJ; Jamalzehi S; Alimohammadi R; Bezvan MH; Mohammadi H; Aslani S
J Cell Physiol; 2019 Jul; 234(7):10018-10031. PubMed ID: 30536757
[TBL] [Abstract][Full Text] [Related]
31. Multipotent Mesenchymal Stromal Cells in Rheumatoid Arthritis and Systemic Lupus Erythematosus; From a Leading Role in Pathogenesis to Potential Therapeutic Saviors?
El-Jawhari JJ; El-Sherbiny Y; McGonagle D; Jones E
Front Immunol; 2021; 12():643170. PubMed ID: 33732263
[TBL] [Abstract][Full Text] [Related]
32. Genetic Polymorphisms Associated with Rheumatoid Arthritis Development and Antirheumatic Therapy Response.
Mikhaylenko DS; Nemtsova MV; Bure IV; Kuznetsova EB; Alekseeva EA; Tarasov VV; Lukashev AN; Beloukhova MI; Deviatkin AA; Zamyatnin AA
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32664585
[TBL] [Abstract][Full Text] [Related]
33. Sympathetic Nerve Hyperactivity in the Spleen: Causal for Nonpathogenic-Driven Chronic Immune-Mediated Inflammatory Diseases (IMIDs)?
Bellinger DL; Lorton D
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29652832
[TBL] [Abstract][Full Text] [Related]
34. Multifaceted role of IL-21 in rheumatoid arthritis: Current understanding and future perspectives.
Dinesh P; Rasool M
J Cell Physiol; 2018 May; 233(5):3918-3928. PubMed ID: 28833093
[TBL] [Abstract][Full Text] [Related]
35. [New therapies for rheumatoid arthritis].
Salgado E; Maneiro JR
Med Clin (Barc); 2014 Nov; 143(10):461-6. PubMed ID: 24461738
[TBL] [Abstract][Full Text] [Related]
36. The role of cytokines in the pathogenesis of rheumatoid arthritis--Practical and potential application of cytokines as biomarkers and targets of personalized therapy.
Brzustewicz E; Bryl E
Cytokine; 2015 Dec; 76(2):527-536. PubMed ID: 26321413
[TBL] [Abstract][Full Text] [Related]
37. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis.
Bartok B; Firestein GS
Immunol Rev; 2010 Jan; 233(1):233-55. PubMed ID: 20193003
[TBL] [Abstract][Full Text] [Related]
38. Modulating the co-stimulatory signal for T cell activation in rheumatoid arthritis: could it be the first step of the treatment?
Caporali R; Bugatti S; Cavagna L; Antivalle M; Sarzi-Puttini P
Autoimmun Rev; 2014 Jan; 13(1):49-53. PubMed ID: 23777823
[TBL] [Abstract][Full Text] [Related]
39. Where do T cells stand in rheumatoid arthritis?
Fournier C
Joint Bone Spine; 2005 Dec; 72(6):527-32. PubMed ID: 16087382
[TBL] [Abstract][Full Text] [Related]
40. B cell-targeted therapy for rheumatoid arthritis: an update on the evidence.
Looney RJ
Drugs; 2006; 66(5):625-39. PubMed ID: 16620141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
